Loading provider…
Loading provider…
Neurology Physician in Detroit, MI
NPI: 1427171677Primary Practice Location
HENRY FORD HEALTH HOSPITAL
2799 W Grand Blvd, Detroit, MI
Primary Employer
Henry Ford Health
henryford.com
HQ Phone
Get M.D., PH.D. Mirela's Phone NumberMobile
Get M.D., PH.D. Mirela's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMI State Medical License
FL State Medical License
2022
MI State Medical License
2002 - 2026

American Board of Psychiatry and Neurology
Neurology
College of Human Medicine - Grand Rapids
humanmedicine.msu.edu
Neurology
Until 2023
Henry Ford Health/Henry Ford Hospital
Residency • Neurology
2003 - 2006
Internship • Transitional Year
2002 - 2003
Wayne State University School Of Medicine
med.wayne.edu
PhD • Anatomy and Cell Biology
1999 - 2002
Neurology
Until 2011
Carol Davila University of Medicine and Pharmacy
Medical School
Until 1988
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 55 | 62 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 36 | 39 |
| 3 | 99204New patient office or other outpatient visit, 45-59 minutes | 18 | 18 |
| 4 | 99222Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 17 | 17 |
| 5 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 13 | 14 |
Authors: Jolliffe, Evan A, Guo, Yong, Hardy, Todd A, Morris, P Pearse, Flanagan, Eoin P, Lucchinetti, Claudia F, Tobin, W Oliver
Journal: Neurology
Publication Date: 2021-05-19
Lead Sponsor: EMD Serono Research & Development Institute, Inc.
Collaborators: Merck KGaA, Darmstadt, Germany
Intervention / Treatment: DRUG: Cladribine
Lead Sponsor: Novartis Pharmaceuticals
Intervention / Treatment: DRUG: Ofatumumab, DRUG: Disease modifying treatment (DMT)
Lead Sponsor: Immunic AG
Intervention / Treatment: DRUG: IMU-838, DRUG: Placebo matching IMU-838